It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hepatic sinusoidal obstruction syndrome (SOS/VOD) represents a dramatic complication of hematopoietic stem cell transplantation (HSCT), particularly in children. Recent evidence has suggested a role for the gut microbiome (GM) in the context of HSCT and its related complications, but no data are available on the relationship between GM and SOS/VOD. Here, we conducted a retrospective case–control study in allo-HSCT pediatric patients developing or not SOS/VOD and profiled their GM over time, from before the transplant up to 72 days after. A rich and diverse GM before HSCT was found to be associated with a reduced likelihood of developing SOS/VOD. Furthermore, prior to transplant, patients not developing SOS/VOD showed an enrichment in some typically health-associated commensals, such as Bacteroides, Ruminococcaceae and Lachnospiraceae. Their levels remained overall higher until post-transplant. This high-diversity configuration resembles that described in other studies for other HSCT-related complications, including graft-versus-host disease, potentially representing a common protective GM feature against HSCT complications.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Pediatric Oncology and Hematology “Lalla Seràgnoli”, Pediatric Unit, Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758); University of Bologna, Department of Medical and Surgical Sciences (DIMEC), Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758)
2 University of Bologna, Unit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758)
3 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Pediatric Oncology and Hematology “Lalla Seràgnoli”, Pediatric Unit, Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758)
4 University of Bologna, Unit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology, Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758); University of Bologna, Department of Medical and Surgical Sciences (DIMEC), Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758)
5 University of Bologna, Department of Medical and Surgical Sciences (DIMEC), Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758)